Provided by Tiger Fintech (Singapore) Pte. Ltd.

BioCardia

1.75
-0.1730-9.01%
Volume:38.70K
Turnover:70.50K
Market Cap:8.18M
PE:-0.60
High:1.94
Open:1.94
Low:1.75
Close:1.92
Loading ...

Company Profile

Company Name:
BioCardia
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
19
Office Location:
320 Soquel Way,Sunnyvale,California,United States
Zip Code:
94085
Fax:
650 631 3731
Introduction:
BioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.

Directors

Name
Position
Andrew Blank
Chairman of the Board
Peter Altman
President, Chief Executive Officer and Director
Jay M. Moyes
Director
Jim Allen
Director
Richard Krasno
Director
Simon H. Stertzer
Director
William Facteau
Director

Shareholders

Name
Position
Peter Altman
President, Chief Executive Officer and Director
David McClung
Chief Financial Officer
Edward Gillis
Senior Vice President of Devices